Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mikiko Kakegawa"'
Autor:
Hisashi Mitsufuji, Masaru Kubota, Masashi Kasajima, Satoshi Igawa, Yoshiro Nakahara, Taihei Ono, Takahiro Ozawa, Takashi Sato, Masanori Yokoba, Seiichiro Kusuhara, Jiichiro Sasaki, Mikiko Kakegawa, Tomoya Fukui, Katsuhiko Naoki
Publikováno v:
Cancer Management and Research. 13:8695-8705
Satoshi Igawa,1 Masashi Kasajima,1 Taihei Ono,1 Takahiro Ozawa,1 Mikiko Kakegawa,1 Seiichiro Kusuhara,1 Takashi Sato,1 Yoshiro Nakahara,1 Tomoya Fukui,1 Masanori Yokoba,2 Masaru Kubota,2 Hisashi Mitsufuji,3 Jiichiro Sasaki,4 Katsuhiko Naoki1 1Departm
Autor:
Hisashi Mitsufuji, Masaru Kubota, Mikiko Kakegawa, Katsuhiko Naoki, Shinji Hosotani, Hiromichi Ishiyama, Takahiro Ozawa, Tomoya Fukui, Masanori Yokoba, Masashi Kasajima, Yasuhiro Hiyoshi, Satoshi Igawa, Seiichiro Kusuhara, Itaru Soda, Jiichiro Sasaki, Masato Katagiri
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 4, Pp 1005-1014 (2020)
Thoracic Cancer, Vol 11, Iss 4, Pp 1005-1014 (2020)
Background The standard treatment for patients with unresectable locally advanced (LA) non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in J
Autor:
Yoshiro Nakahara, Jiichiro Sasaki, Tomoya Fukui, Taihei Ono, Takahiro Ozawa, Seiichiro Kusuhara, Katsuhiko Naoki, Mikiko Kakegawa, Mitsufuji Hisashi, Takashi Sato, Masashi Kasajima, Satoshi Igawa
Publikováno v:
Investigational new drugs. 40(2)
Objective: The clinical outcomes of poor performance status (PS) patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib as a first-line treatment have not been sufficiently ev
Autor:
Satoshi, Igawa, Masashi, Kasajima, Taihei, Ono, Takahiro, Ozawa, Mikiko, Kakegawa, Seiichiro, Kusuhara, Takashi, Sato, Yoshiro, Nakahara, Tomoya, Fukui, Masanori, Yokoba, Masaru, Kubota, Hisashi, Mitsufuji, Jiichiro, Sasaki, Katsuhiko, Naoki
Publikováno v:
Cancer Management and Research
Background The clinical outcomes of elderly patients with EGFR-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib have not been sufficiently evaluated. This study aimed to assess the efficacy and safety of osimertinib in elde
Autor:
Jiichiro Sasaki, Satoshi Igawa, Kazuto Nishio, Kazuhiko Nakagawa, Kazuko Sakai, Tomoya Fukui, Hisashi Mitsufuji, Katsuhiko Naoki, Mikiko Kakegawa, Takayuki Takahama, Masayuki Takeda
Publikováno v:
Cancer biomarkers : section A of Disease markers. 31(2)
BACKGROUND: The advancement of cancer genomics has allowed for multiplex gene assays using next-generation sequencing (NGS) to be practically implemented, however, a clinical practice system remains to be established. OBJECTIVE: We evaluated the feas